Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Onyx Pharmaceuticals
Information provided by (Responsible Party):
Oncotherapeutics
ClinicalTrials.gov Identifier:
NCT01365559
First received: May 31, 2011
Last updated: July 9, 2014
Last verified: July 2014
  Purpose

This is a phase I/II multicenter, open label, nonrandomized study for patients with Multiple Myeloma (MM) who will receive treatment with carfilzomib in place of bortezomib using the same bortezomib-containing combination regimen to which a MM patient has progressed while receiving. This study will enroll 45 patients total. These patients will be resistant to bortezomib as demonstrated by progressive disease while on bortezomib or have relapsed within 12 weeks of the last dose of bortezomib in a combination regimen. Patients will be sub-divided into 2 groups in this study, treatments containing (Group A) or not containing immunomodulatory drugs (IMiDs) (Group B). Thirty patient will be enrolled into Group A and 15 patients into Group B for a total of 45 patients. Patients must have received 4 doses of a minimum of 1.0 mg/m^2 of bortezomib in no more than 4 weeks per cycle. Patients must have received at least one cycle meeting this definition and have shown progressive disease to be considered eligible. Patients who have been refractory to or relapsed within 12 weeks of the last dose of bortezomib in their most recent bortezomib-containing regimen that does not include either thalidomide or lenalidomide are eligible regardless of when patients received that regimen, as long as they meet the above criteria.

Carfilzomib will subsequently replace bortezomib using the patient's most recent bortezomib-containing regimen to which the patient progressed while receiving. Patients will be eligible if they progressed from bortezomib with an alkylating agent (melphalan or cyclophosphamide), an anthracycline (doxorubicin or pegylated liposomal doxorubicin) and/or a glucocorticosteroid (prednisone, dexamethasone or medrol)and IMiD (thalidomide or lenalidomide). The study will consist of a screening period, followed by up to eight open label treatment cycles, a final assessment to occur 28 days after the end of the last treatment cycle, a follow-up period and maintenance cycles of single agent carfilzomib.

Patient who complete the combination treatment period without progressive disease will be eligible for maintenance therapy with single-agent carfilzomib. During maintenance therapy carfilzomib will be administered at the same dose given during the last cycle of combination treatment.


Condition Intervention Phase
Multiple Myeloma
Drug: Group A: Carfilzomib & Non-IMiD Regimen
Drug: Group B: Carfilzomib & IMiD containing regimen.
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Carfilzomib as a Replacement for Multiple Myeloma Patients Failing Bortezomib-containing Regimens

Resource links provided by NLM:


Further study details as provided by Oncotherapeutics:

Primary Outcome Measures:
  • Establish MTD, determine DLT and to determine the efficacy as assessed by the overall response rate. [ Time Frame: Montly ] [ Designated as safety issue: Yes ]

    Phase I:

    • To establish the maximum tolerated dose (MTD) and determine the dose limiting toxicities (DLT) following treatment.

    Phase II:

    • To determine the efficacy as assessed by the overall response rate [CR + VGPR + PR + MR] and the Time to Progression (TTP) of disease.



Secondary Outcome Measures:
  • To establish safety and efficacy following treatment. [ Time Frame: Montly ] [ Designated as safety issue: Yes ]

    Phase I:

    Obtain preliminary evidence of efficacy following treatment based on:

    • SPEP, UPEP and quantification of serum immunoglobulins
    • Bone marrow aspirates & biopsies
    • B2M
    • A roentgenographic skeletal survey of bones

    Phase II:

    Establish the safety & tolerability following treatment based on:

    • Adverse events
    • Clinical lab tests
    • Vital signs
    • Medical history & body weight measurements
    • ECOG performance status
    • Concomitant medication usage

    Both phases:

    Progression Free Survival among patients who continue onto maintenance treatment



Estimated Enrollment: 45
Study Start Date: April 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A: Carfilzomib & Non-IMiD containing regimen
Bortezomib is replaced with carfilzomib in a combined regimen identical to the patient's previous regimen. Regimen cannot include thalidomide or lenalidomide.
Drug: Group A: Carfilzomib & Non-IMiD Regimen

Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.

Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.

Maintenance regimen maybe administered if patient does not progress while on study.

Experimental: Group B: Carfilzomib & IMiD containing regimen.
Bortezomib is replaced with carfilzomib in a regimen that includes IMiDs (lenalidomide or thalidomide). Thus, the regimen is carfilzomib in an IMiD-containing regimen.
Drug: Group B: Carfilzomib & IMiD containing regimen.

Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.

Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.

Maintenance regimen maybe administered if patient does not progress while on study.


  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion:

Disease-related:

  1. Have a diagnosis of MM based on standard criteria
  2. Currently has MM with measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 gm/dL and/or urine monoclonal immunoglobulin amount of at least 200 mg/24 hours.
  3. Have relapsed within 12 weeks of receiving or is refractory to their most recent bortezomib-containing regimen as long as they meet the following criteria:

    • Progressed from bortezomib-containing regimen either as a single agent or in combination with an alkylating agent (melphalan or cyclophosphamide), an anthracycline (doxorubicin or pegylated liposomal doxorubicin), IMiDs (thalidomide or lenalidomide), and/or a glucocorticosteroid (prednisone, dexamethasone or medrol)
    • Bortezomib must have been administered at 4 doses of a minimum of 1.0 mg/m2 in no more than 28 days per cycle. Subjects must have received at least one cycle meeting this definition and have shown progressive disease to be considered eligible.
    • Subject who have been refractory to their most recent bortezomib-containing regimen are eligible regardless of when the subject received that regimen, as long as they meet the above criteria and have been off the treatment for > 3 weeks.

    Definition of refractory disease: patients who meet criteria for progressive disease while currently receiving treatment.

    Demographics:

  4. Age ≥ 18 years
  5. Life expectancy ≥ 3 months
  6. ECOG performance status 0-2 at study entry

    Laboratory tests (within 14 days prior to drug dosing on Cycle 1, Day 1)

  7. Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; if the bone marrow is extensively infiltrated (> 70% plasma cells) then 1.0 x 109/L
  8. Hemoglobin ≥ 8 g/dL (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
  9. Platelet count ≥ 75 × 109/L; if the bone marrow is extensively infiltrated (> 70% plasma cells) then 50 x 10^9/L
  10. Creatinine clearance (CrCl) ≥ 30 mL/minute either measured or calculated. Subject with a creatinine > 15mL/min and < 30 mL/min due to significant myelomatous involvement of the kidneys may be enrolled in the study after receipt of approval from Oncotherapeutics.
  11. Adequate hepatic function, with AST (SGOT) and ALT (SGPT) 3 x upper limit of normal (ULN) or 5 x ULN if hepatic metastases are present and serum total bilirubin ≤ 1.5 x ULN
  12. Serum potassium > 3 and < 5

    Ethical/Other

  13. Written informed consent in accordance with federal, local, and institutional guidelines.
  14. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception.
  15. Male subjects must agree to practice contraception.

Exclusion:

Disease-related

  1. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes (POEMS) syndrome
  2. Plasma cell leukemia
  3. Severe hypercalcemia, i.e., serum calcium 12 mg/dL (3.0 mmol/L) corrected for albumin
  4. Received the following prior therapy:

    • Chemotherapy within 21 days of enrollment (6 wks for nitrosoureas)
    • Corticosteroids (>10 mg/day prednisone or equivalent) within 21 days of enrollment
    • Immunotherapy or antibody therapy as well as thalidomide, lenalidomide, arsenic trioxide, or bortezomib within 21 days before enrollment
    • Radiation therapy within 21 days before enrollment, receipt of localized radiation therapy does not preclude enrollment
    • Use of any other experimental drug or therapy within 28 days of enrollment

    Concurrent Conditions

  5. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

    • Unstable angina or myocardial infarction within 4 months prior to enrollment
    • NYHA Class III or IV heart failure
    • Uncontrolled angina
    • Clinically significant pericardial disease
    • Severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
  6. Pregnant or lactating females
  7. Major surgery within 28 days prior to enrollment or has not recovered from side effects of such therapy (Kyphoplasty is not considered to be a major surgical procedure; however, the investigator is to discuss enrollment of a patient with a recent history of kyphoplasty with Oncotherapeutics).
  8. Acute active infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 14 days prior to receiving first dose of study drug
  9. Known human immunodeficiency virus infection; baseline testing is not required
  10. Active hepatitis B or C infection; baseline testing is not required
  11. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
  12. Nonhematologic malignancy within the past 5 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
  13. Concurrent use of other anti-cancer agents or treatments
  14. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to enrollment
  15. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
  16. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment
  17. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01365559

Locations
United States, California
Pacific Oncology and Hematology
Encinitas, California, United States, 92024
Pacific Cancer Care
Salinas, California, United States, 93901
Central Coast Medical Oncology
Santa Maria, California, United States, 93454
James R. Berenson, MD, Inc.
West Hollywood, California, United States, 90069
United States, Illinois
Cancer Centers of America
Zion, Illinois, United States, 60099
United States, Indiana
Franciscan St. Francis Health
Indianapolis, Indiana, United States, 46237
United States, Maryland
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
United States, Tennessee
Family Cancer Center Foundation, Inc.
Memphis, Tennessee, United States, 38119
United States, Virginia
Virginia Cancer Specialists
Fairfax, Virginia, United States, 233031
Sponsors and Collaborators
Oncotherapeutics
Onyx Pharmaceuticals
Investigators
Principal Investigator: James R Berenson, MD James R. Berenson, MD., Inc.
  More Information

No publications provided

Responsible Party: Oncotherapeutics
ClinicalTrials.gov Identifier: NCT01365559     History of Changes
Other Study ID Numbers: IST-CAR-516
Study First Received: May 31, 2011
Last Updated: July 9, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Oncotherapeutics:
multiple myeloma
carfilzomib
relapsed
refractory
bortezomib
Oncotherapeutics

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bortezomib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 29, 2014